HSP90B2P and nasopharyngeal carcinoma: The study also aimed to characterize novel biomarkers associated with the altered NPC1/2 protein function and lipid metabolism in NPC disease, monitoring their expression longitudinally, in order to establish a set of biomarkers for NPC and for interventions targeting the HSP system in NPC (Orphazyme protocol number: CT-ORZY-NPC-001; ClinicalTrials.gov ID: NCT02435030) [39].